Status:
COMPLETED
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
Lead Sponsor:
Vistakon Pharmaceuticals
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
Eligibility Criteria
Inclusion
- history of positive diagnostic test for ragweed within the past 2 years;
- positive bilateral response to ragweed as induced by conjunctival allergen challenge
Exclusion
- ocular infection;
- history of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
- moderate to severe asthma;
- dry eye syndrome;
- history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal or autoimmune disease;
- pregnancy or lactation
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
365 Patients enrolled
Trial Details
Trial ID
NCT00364091
Start Date
August 1 2006
Last Update
September 27 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Louisville, Kentucky, United States
2
North Andover, Massachusetts, United States
3
Creve Coeur, Missouri, United States
4
Charlotte, North Carolina, United States